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Abstract
Background: To examine whether a simple Visual Analogue Mood Scale (VAMS) is able to predict time to relapse over 5.5-
years.
Methodology/Principal Findings: 187 remitted recurrently depressed out-patients were interviewed using the Structured
Clinical Interview for DSM-IV Axis I Disorders (SCID-I) and the 17-item Hamilton Depression rating scale (HAM-D) to verify
remission status (HAM-D ,10). All patients rated their current mood with the help of a Visual Analogue Mood Scale (VAMS)
at baseline and at a follow-up assessment three months later. Relapse over 5.5-years was assessed by the SCID-I. Cox
regression revealed that both the VAMS at baseline and three months later significantly predicted time to relapse over 5.5-
years. Baseline VAMS even predicted time to relapse when the number of previous depressive episodes and HAM-D scores
were controlled for. The baseline VAMS explained 6.3% of variance in time to relapse, comparable to the HAM-D interview.
Conclusions/Significance: Sad mood after remission appears to play a pivotal role in the course of depression. Since a
simple VAMS predicted time to relapse, the VAMS might be an easy and time-effective way to monitor mood and risk of
early relapse, and offers possibilities for daily monitoring using e-mail and SMS.
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Introduction
Major Depressive Disorder (MDD) is a recurrent disorder with
80% risk of relapse in the absence of adequate treatment [1]. After
remission, residual symptoms are a consistent predictor of relapse
[2,3]. Since residual symptoms are known to fluctuate within
patients [4], thorough and frequent monitoring after remission is
important in order to detect potential relapse.
The semi-structured Hamilton Depression rating scale (HAM-
D) interview [5] is one of the most frequently used instruments to
monitor patients and assess depressive symptomatology [6].
Higher scores on the HAM-D have been found to predict relapse
[7–10]. Nevertheless, administration of the HAM-D has some
disadvantages including its extensive length (similar to self-report
measures; IDS-SR: 30 items, BDI-II: 21 items), time required for
administration, and reliance on training [11,12]. Unidimensional
subscales (six up to 14 items) derived from the HAM-D were
comparable to the total HAM-D in predicting which patients had
remitted from acute MDD [13–18]. However, even less extensive
versions of the HAM-D are time consuming and rely on training.
Depressed mood after remission appears to be an important
symptom in the process of relapse. A recent study demonstrated
that depressed mood after remission, as assessed by the Mood
Spectrum Self-report Questionnaire, was predictive of relapse over
6 months in remitted patients [19]. Moreover, mood reactivity to a
sad mood provocation (i.e. increases in sad mood) was a
vulnerability factor in 48 remitted depressed patients [20], and
predicted relapse over 5.5-years prospectively in 172 remitted
recurrently depressed patients [21]. Depressed mood is also among
the symptoms experienced in both the prodromal and the residual
phase of depression [22]. This finding provides empirical support
for the rollback theory in which residual symptoms are considered
prodromal symptoms for the next depressive episode [22–24].
Mood can be assessed within one minute with a simple Visual
Analogue Mood Scale (VAMS), on which patients rate their
current mood by placing a single mark on a simple 10-centimeter
line with ‘happy’ and ‘sad’ on either side. Indication of current
mood using a 10-centimeter black line was found to correlate with
HAM-D (r= .79; anchors ‘normal’ to ‘most depressed’) and BDI
(r= .58; anchors ‘not at all depressed’ to ‘most depressed’) scores
and was also able to detect clinical change [25–30]. Benefits of a
VAMS include the limited amount of time and absence of clinical
training required, easy comprehensibility, and easy application
throughout daily life of a high risk patient. Moreover, the VAMS
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offers opportunities for mood monitoring via internet and text
messages. We are unaware of any studies using a VAMS in the
prediction of relapse in depression.
Therefore the current study is the first to examine a) whether a
VAMS predicts time to relapse in depression over 5.5-years in
patients currently in remission from MDD, and b) the amount of
variance explained in predicting time to relapse by the VAMS
alone as well as c) when added to the HAM-D interview and vice
versa.
Methods
Participants
The current study was part of a Randomized Controlled Trial
comparing the effectiveness of preventive Cognitive Therapy (CT)
added to Treatment As Usual (TAU) and compared to TAU alone
in the prevention of relapse. The protocol was approved by the
Amsterdam Medical Center ethical board. All patients provided
written informed consent prior to participation in the study (see
[31,32] for more details). All participants of the RCT participated
in the current study. In order to participate in the study patients
had a) experienced two or more Major Depressive Episodes
(MDEs) in the previous five years and b) current remission of
MDE for at least 10 weeks but no longer than two years both
defined according to the Diagnostic and Statistical Manual of Mental
Disorders (DSM–IV, [33]) and assessed with the Structured Clinical
Interview for DSM–IV (SCID, [34]) administered by trained
interviewers; and c) a current score of ,10 on the HAM-D.
Exclusion criteria were: current mania or hypomania or a history
of bipolar illness, any psychotic disorder (current and previous),
organic brain damage, alcohol or drug abuse, predominant
anxiety disorder, recent electroconvulsion therapy, recent cogni-
tive treatment or receiving CT at the start of the study, or current
psychotherapy with a frequency of more than twice a month.
Measures
Visual analogue mood scale. Patients were asked to rate
their current mood at baseline and three months after baseline by
placing a cross on a Visual Analogue Mood Scale (VAMS) with
the following instruction: ‘You can answer the following question
by placing a cross on the line from 0 to 10: at the moment I feel.’.
The VAMS measured 100 mm between the two anchors with the
descriptor ‘‘happy’’ located to the left of the center while ‘‘sad’’
was located on the right.
17-item Hamilton Depression Rating Scale
The 17-item Hamilton Depression rating scale (HAM-D, [5])
was used by telephone [35] to assess levels of depressive
symptomatology at baseline and three months after baseline. This
widely used semi-structured interview covers affective, behavioral
and biological symptoms with scores that range between 0 and 52.
The HAM-D was administered by trained research assistants and
psychologists who were blind to treatment condition. Second
ratings (n=17) demonstrated high intraclass correlation (r = .94),
indicating high agreement.
Relapse/recurrence
The main outcome measure was time to relapse/recurrence
assessed using the SCID-I. Current and past MDEs were checked
for all patients at five assessment-points (3, 12, 24, 36 and 66
months). To keep the assessors blind with respect to treatment
condition, we instructed participants not to reveal this information
to the interviewers. Kappa (k) for interrater agreement on relapse
between the interviewers and an independent psychiatrist, assessed
over the assessment period, ranged between 0.94 to 0.96,
indicating excellent agreement.
Use of Antidepressant Medication (ADM)
Patients were asked about their use of ADM for the last
depression before entry of the study and whether they continued
using ADM after remission [36,37]. During the first two years of
the study, every three months, information on ADM (type and
dosage) over the previous month was monitored using the
Trimbos/iMTA Self-Report Questionnaire for Costs associated
with Psychiatric Illness [38], which covers a maximum recall
period of one month. Additionally, information on continuous use
was also collected by the interviewer during the 24, 36 and 66
month interviews retrospectively. Adherence was assessed with the
Medication Adherence Questionnaire (MAQ) [39].
Statistical Analysis
First of all, we were interested in the prediction of time to
relapse within 5.5-years by the VAMS at the two available
assessment-points (baseline and three months after baseline). We
used survival analysis (Cox regression) in which patients who
dropped-out or who did not relapse within 5.5-years were treated
as censored. Since use of ADM and number of previous episodes
might influence VAMS scores, we checked all models for
confounding by these variables.
To assess whether CT moderated the relation between the
predictors and relapse, we examined the two-way interaction of
Condition x predictor and the three-way interaction of Condition
x predictor x Previous MDEs since in a previous study the number
of previous MDEs was a moderator of predictors of interest on
relapse [31,32]. If CT affected this relation the analyses was
restricted to the control group only, otherwise the analysis was
performed on the complete sample.
Moreover, we were interested in the amount of variance
explained in time to relapse by the VAMS and the HAM-D
interview. Since Cox regression does not provide a measure for
explained variance directly, we calculated explained variance
using Nagelkerke’s R2 [40] formula. We calculated explained
variance for a model containing the VAMS only, as well as two
combined models in which the HAM-D was entered in the first
block whereas the VAMS was entered in the second block and vice
versa.
Results
Patient Characteristics and Flow
In total 187 formerly depressed patients were included in the
study. For the analyses we excluded 15 patients (drop-outs),
resulting in a remaining 172 patients. Drop-outs were slightly
younger (t(170) =22.25, p=0.03), but did not differ on any other
characteristic.
Demographic and clinical characteristics are summarized in
Table 1. Patients were predominantly female (74%) and were
currently in remission of a highly recurrent MDD (median number
of MDEs: 4.0) with 3.8 residual symptoms (HAM-D) on average.
Preliminary VAMS Analyses
The VAMS at baseline and three months later demonstrated
moderate stability and were significantly associated (r= .30;
p,0.001). After controlling for depressive symptoms (HAM-D)
at three months after baseline, both VAMS measurements
remained significantly associated (r= .25; p=0.001).
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Prediction of Relapse Using the VAMS
Since none of the interaction terms were significant and neither
the number of previous MDEs nor use of ADM confounded the
predictor of interest, interaction terms were subsequently dropped
from the model and Cox regression was fitted with the individual
predictor only (see Table S1, S2 for interaction coefficients).
Cox regression revealed that the baseline VAMS significantly
predicted time to relapse in 5.5-years (Wald x (2,1) = 11.758,
p = 0.001, hazard ratio = 1.15). Each centimeter increase on the
VAMS increased the prospective risk of relapse with a factor 1.15
(15%). The baseline VAMS remained a significant predictor up
and above the most consistent predictors of relapse, the total
HAM-D and the number of previous MDEs.
In order to replicate prediction of relapse by a single VAMS in
the current sample, we subsequently investigated whether a single
VAMS administered three months after baseline was also
predictive of relapse. Again, a single VAMS predicted time to
relapse in 5.5-years (Wald x (2,1) = 7.091, p = 0.008, hazard
ratio = 1.12), though this time not up and above the total HAM-D.
Comparing Explained Variance of the Baseline VAMS to
the HAM-D
A previous study on this sample already demonstrated that the
total baseline HAM-D predicted time to relapse, and explained
6.0% in variance of time to relapse over 5.5-years [10].
We were now interested in the amount of variance explained
by the baseline VAMS, which was 6.3% (comparable between
conditions, 5.5% for TAU and 6.8% for TAU+CT). Second,
when the VAMS was added to a model already containing the
HAM-D, explained variance of the model increased from 6.0%
to 10.3%. Likewise, when the total HAM-D was added to a
model already containing the VAMS, an additional 4.1% was
explained.
Discussion
The current study focused on the question whether a simple
Visual Analogue Mood Scale (VAMS) predicted time to relapse in
depression over 5.5-years, and how well the VAMS predicted time
to relapse compared to the HAM-D.
The current study demonstrated that even a simple VAMS was
able to predict time to relapse for 5.5-years in recurrently
depressed patients currently in remission. Both VAMS measure-
ments (at baseline and three months later) predicted time to
relapse and were significantly associated to each other. The
baseline VAMS even predicted relapse up and above a frequently
used depression interview, i.e. the HAM-D interview. Our findings
stress the relevance of mood as a risk factor for relapse, which is in
line with previous studies [19–21].
Moreover, the baseline VAMS predicted time to relapse for 5.5-
years comparable to the HAM-D interview in terms of explained
variance. When the VAMS was added to the HAM-D, additional
variance was explained. However, the same was true when HAM-
D was added to the VAMS, suggesting differences in what both
instruments measure. Nevertheless, the predictive power of the
VAMS as well as the HAM-D was indicative of a small effect size
(6% in variance). Potentially, when assessed repeatedly, explained
variance of the VAMS might increase.
Previous use of a Visual Analogue Scale in patients already
demonstrated high convergent validity (r= .85) and test re-test
reliability (r= .96) in the improvement of winter depression in
162 patients receiving light therapy [41]. Furthermore, a Visual
Analogue Scale was also able to detect depressive symptoms
among 157 elderly patients with cognitive impairments [42], but
also in patients suffering from somatic illnesses including
coronary syndrome [43] and diabetes mellitus [44]. The current
study extends the use of a VAMS to the prediction of relapse in
depression. The VAMS is easily administered in less than a
minute and might be a feasible way to assess patients at high
risk of relapse in clinical practice. Moreover, the VAMS could
be used in combination with the HAM-D in stepwise
monitoring, as a tool for early detection of relapse using new
devices including mobile phone applications, short message
service and e-mail monitoring [45–48]. When mood on the
VAMS appears to be low, monitoring could be intensified using
the HAM-D interview.
Several limitations of the current study have to be noted.
First of all, since Cox regression does not provide explained
variance directly, explained variance had to be calculated using
Nagelkerke’s R2 [40]. The amount of variance explained should
therefore be considered as an estimation. Second, although we
checked our analyses for confounding by baseline use of ADM,
we cannot completely rule out the potential influence of ADM
on prediction by the VAMS later in the study since actual use
was monitored only twice (retrospectively) in the final 3.5-years
of the study. Third, the three-month stability of the VAMS used
in the current study was maximal moderate. The use of this
simple and quick screening instrument might thus result in
decreases in reliability. Finally, lack of standardization of the
VAMS has resulted in many different one-item mood scales.
While in the current study, similar to previous studies [49–51],
‘happy’ and ‘sad’ were used as anchors, other anchors have
been described in the literature as well, i.e. ‘neutral’ to ‘sad’,
‘not at all depressed’ to ‘most depressed’, ‘worst mood’ to ‘best
mood’ [26–28,52], which makes it difficult to compare the
VAMS among studies and could explain differences in results. It
is currently unknown which anchors are most reliable in
measuring mood. Future studies should therefore focus on
optimizing the VAMS scale by determining the most sensitive
and reliable anchor points. Furthermore, since previous studies
indicate that mood and fluctuations in mood are related to
relapse [19–21] studies should include repeated assessment of
mood (daily sampling) to study the stability of mood and
thereby enhance early detection of relapse.
Table 1. Demographic and Clinical Characteristics at Baseline.
TAU (n=84) TAU + CT (n=88)
Demographicsa
Female % (n) 74.0 (62) 73.0 (64)
Age 43.4 (9.8) 45.9 (9.1)
Median previous episodes
(IQR)
3.0 (3.8) 4.0 (3.8)
Age of first onset 28.1 (12.5) 28.9 (12.6)
Patients on antidepressants
% (n)
50.0 (42.0) 52.0 (46.0)
Clinical characteristics
VAMSbaseline 37.0 (21.0) 34.0 (20.0)
VAMSthree months 33.0 (19.0) 32.0 (18.0)
Total HAM-D17 3.7 (2.9) 3.8 (2.8)
Note. TAU= Treatment As Usual, CT = Cognitive Therapy, IQR = Interquartile
Range, VAMS=Visual Analogue Mood Scale.
aAll values represent mean (SD) unless stated otherwise.
doi:10.1371/journal.pone.0046796.t001
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